Mit zwei Final-Studien für Brust und Leberkrebs in der Pipeline ist diese Aktie mit rund 35 Mio$ Marktkapitalisierung vieeeeeeel zu billig . Die Aktie ist weder hier noch an der Heimatbörse nicht sonderlich bekannt und genau das bietet eine Riesenchance das bedeutet einsteigen bevor die Aktie von der Masse entdeckt wird .
(1) ThermoDox(R) ...Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox(R) clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
(2) About ThermoDox Global Phase III HEAT Study ...Based on an historical review of RFA cases, Celsion expects the study could be completed by the middle of 2011
Celsion's Technology Is the Focus of 6.4 Million EUR 'HIFU-CHEM' Program To Study ThermoDox(R) and MRI-guided HIFU Project Will Focus on Early Development and Investigate Treatment Options for Two Indications: Liver and Bone Metastases
Press Release Source: Celsion Corporation On Monday February 22, 2010, 7:30 am
1st data set analysis from RCW Phase I/II trial 12/10
First drug, ThermoDox®, is in 2 registrational trials with near term commercialization • ThermoDox addresses $ billion market potential
• Strong IP patent protection to 2018 with extension potential, Orphan Drug designation in US
• Commercialization plans maximize shareholder value • US strategy is to market and sell directly • Ex-US strategy is through license agreements with Pharma partners
genau aus dem Grund würde ich mir nie ne Ami-Biobude ins Depot holen...das ist exorbiant wie die bei versemmelten Studien und Projekten abgestraft werden.
----------- 100 % food speculation free - Don`t let your money kill people ! Respect Africa !
|
Thread abonnieren
